Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis

Saeed Vaheb, Mahour Farzan, Alireza Afshari‑Safavi, Narges Ebrahimi, Vahid Shaygannejad, Omid Mirmosayyeb

Abstract


Background: Fampridine is the only drug approved by the US Food and Drug Administration (FDA) for people with multiple sclerosis (MS) to improve their movement and has exhibited a clinically significant improvement in gait function in a subset of MS patients with Expanded Disability Status Scale (ESDSS) from 4 to 7. Nevertheless, this drug has been reported to possess some adverse effects (AEs) like seizure because of its pharmacological features. The aim of this study was to evaluate the incidence rate of post‑medication side effects (SEs) of fampridine in MS patients. Methods: This prospective cohort study includes MS patients aged between 18 and 65 years, referred to the neurology clinic of Kashani Hospital from April 2022 to October 2022, all with administration of fampridine (10 mg tablet twice daily according to the product specifications). Safety in these patients was monitored through monthly SEs checklist questions during 6 months of screening. SPSS version 18 was used to analyze the data of this study. Results: From 319 participants screened at baseline, 254 patients with MS, including 127 relapsing‑remitting multiple sclerosis (RRMS), 101 secondary progressive multiple sclerosis (SPMS), and 26 primary progressive multiple sclerosis (PPMS), were included in the study. The most observed AEs in SPMS and RRMS patients were dry mouth (13.9% vs. 15%) and insomnia (12.9% vs. 11%), respectively. Urinary tract infection (UTI) (11.5%) and stomachache (11.5%) were the most common SEs in PPMS patients. The most severe complication of the patients was back pain, while digestive complications were less severe. Also, insomnia and UTI were the patients’ most persistent SEs. Conclusions: The drug seems to be safe and well tolerated, as the SEs were mild and transient and they were consistent with most of the previous studies focusing on this medication.

Keywords


Drug adverse reactions; fampridine; multiple sclerosis; safety

Full Text:

PDF

References


Filser M, Buchner A, Fink GR, Gold SM, Penner I K. The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools. J Neurol 2023;270:171 207.

Hagiwara A, Otsuka Y, Andica C, Kato S, Yokoyama K, Hori M, et al. Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorders by multiparametric quantitative MRI using convolutional neural network. J Clin Neuroscience 2021;87:55 8.

Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med (Lond) 2020;20:380 3.

Correale J, Marrodan M, Benarroch EE. What is the role of axonal ion channels in multiple sclerosis? Neurology 2020;95:120 3.

Harguindey S, Alfarouk K, Polo Orozco J, Reshkin SJ, Devesa J. Hydrogen ion dynamics as the fundamental link between neurodegenerative diseases and cancer: Its application to the therapeutics of neurodegenerative diseases with special emphasis on multiple sclerosis. Int J Mol Sci 2022;23:2454.

Viswanathan S. Regional and global perspectives on the incidence of multiple sclerosis and neuromyelitis optica and its spectrum disorders from Asia with emphasis on China. Lancet Reg Health West Pac 2020;3:100039.

Shah VV, McNames J, Mancini M, Carlson Kuhta P, Spain RI, Nutt JG, et al. Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson’s disease and matched controls during daily living. J Neurol 2020;267:1188 96.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, et al. Prolonged release fampridine in multiple sclerosis: Clinical data and real world experience. Report of an expert meeting. Ther Adv Neurol Disord 2018;11:1756286418803248.

Rommer P, Zettl UK. Treatment options in multiple sclerosis and neuromyelitis optica spectrum disorders. Curr Pharm Des 2022;28:428 36.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494 502.

Ghorbanpour S, Rahimibarghani S, Rohani S, Rastkar M, Ghajarzadeh M. Fampridine for gait imbalance in patients with multiple sclerosis (MS): A systematic review and meta analysis. Neurol Sci 2023;44:3059 69.

Arpín EC. Efficacy and safety of fampridine for walking disability in multiple sclerosis. Neurodegener Dis Manag 2020;10:277 87.

Cornblath DR, Bienen EJ, Blight AR. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther 2012;34:1056 69.

Kim ES. Fampridine prolonged release: A review in multiple sclerosis patients with walking disability. Drugs 2017;77:1593 602.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444 52.

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an International survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996;46:907 11.

Krishnan AV, Kiernan MC. Sustained release fampridine and the role of ion channel dysfunction in multiple sclerosis. Mult Scler J 2013;19:385 91.

Etemadifar M, Saboori M, Chitsaz A, Nouri H, Salari M, Khorvash R, et al. The effect of fampridine on the risk of seizure in patients with multiple sclerosis. Mult Scler Relat Disord 2020;43:102188.

Shah VV, McNames J, Mancini M, Carlson Kuhta P, Spain RI, Nutt JG, et al. Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson’s disease and matched controls during daily living. J Neurol 2020;267:1188 96.

Young EA, Fowler CD, Kidd GJ, Chang A, Rudick R, Fisher E, et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008;63:428 35.

Cherchi F, Bulli I, Venturini M, Pugliese AM, Coppi E. Ion channels as new attractive targets to improve re myelination processes in the brain. Int J Mol Sci 2021;22:7277.

Krishnan AV, Kiernan MC. Sustained release fampridine and the role of ion channel dysfunction in multiple sclerosis. Mult Scler J 2012;19:385 91.

Liu Y, Wang K. Exploiting the diversity of ion channels: Modulation of ion channels for therapeutic indications. Handb Exp Pharmacol 2019;260:187 205.

Filli L, Zörner B, Kapitza S, Reuter K, Lörincz L, Weller D, et al. Monitoring long term efficacy of fampridine in gait impaired patients with multiple sclerosis. Neurology 2017;88:832 41.

Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, et al. A Prospective, observational, cohort study to assess the efficacy and safety of prolonged release fampridine in cognition, fatigue, depression, and quality of life in multiple sclerosis patients: The FAMILY study. Adv Ther 2021;38:1536 51.

Broicher SD, Filli L, Geisseler O, Germann N, Zörner B, Brugger P, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol 2018;265:1016 25.

Boffa L, Albanese M, Ziccardi L, Aiello F, Cesareo M, Parisi V, et al. Fampridine improves acute optic neuritis contributing to a long lasting recovery of nerve function. Neurol Sci 2021;42:4833 6.

Wu Z Z, Li D P, Chen S R, Pan H L. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage activated calcium channel beta subunit. J Biol Chem 2009;284:36453 61.

Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, et al. The effects of 4 aminopyridine in multiple sclerosis patients: Results of a randomized, placebo controlled, double blind, concentration controlled, crossover trial. Neurology 1994;44:1054 9.

Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained release 4 aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817 21.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, et al. Dose comparison trial of sustained release fampridine in multiple sclerosis. Neurology 2008;71:1134 41.

Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, et al. Fampridine SR in multiple sclerosis: A randomized, double blind, placebo controlled, dose ranging study. Mult Scler 2007;13:357 68.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained release oral fampridine in multiple sclerosis: A randomised, double blind, controlled trial. Lancet 2009;373:732 8.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, et al. Long term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open label extensions of two Phase 3 clinical trials. Mult Scler 2015;21:1322 31.

Jara M, Aquilina T, Aupperle P, Rabinowicz AL. Safety profile of dalfampridine extended release in multiple sclerosis: 5 year postmarketing experience in the United States. Drug Healthc Patient Saf 2015;7:169 74.

Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, et al. Prolonged release fampridine and walking and balance in MS: Randomised controlled MOBILE trial. Mult Scler 2016;22:212 21.

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, et al. Assessment of clinically meaningful improvements in self reported walking ability in participants with multiple sclerosis: Results from the randomized, double blind, phase III ENHANCE trial of prolonged release fampridine. CNS Drugs 2019;33:61 79.